The larger of the two deals saw Roche spend $110 on forming a strategic collaboration with the clinical-stage biopharmaceutical company Poseida Therapeutics, to develop allogeneic CAR-T therapies targeting hematological malignancies.
This partnership will see Roche receive exclusive rights to develop Posedia’s existing off-the-shelf CAR-T products for multiple myeloma, B-cell lymphomas, and other blood cancers, including Poseida’s BCMA and dual CD19-CD20 candidates, with the aim to commercialize these treatments.
This collaboration will also see both companies embark on an 18-month research project to develop next-generation allogeneic CAR-T therapy candidates for new and existing hematological targets.
“Roche is an ideal strategic partner for Poseida with its industry-leading R&D capabilities in oncology, complementary technologies and expertise, and global regulatory and commercial capabilities. Working together, we look forward to advancing novel allogeneic cell therapies based upon Poseida’s technologies for patients battling cancer,” said Mark Gergen, CEO of Poseida.
The partnership outlines that Podeida will manufacture the clinical materials and conduct the Phase I studies of its existing products and any future collaborative products, before passing the programs to Roche, who will be responsible for late-stage clinical development and global commercialization.
On top of the $110 upfront payment, Poseida is set to receive up to $110 million in product milestones over the next few years. They will also see additional payments for research, development, launch, and net sales across multiple programs, to a potential aggregated value of $6 billion.
“Poseida’s differentiated platform technologies complement our ongoing internal efforts and partnerships to discover and develop cell therapies as a next generation of medicines for patients,” commented James Sabry, Global Head of Pharma Partnering at Roche.
Roche’s second deal of the week, through its Genetech unit, is an $80m upfront payment to Kiniksa Therapeutics to secure a global license of their antibody candidate vixarelimab, targeting oncostatin M receptor beta.
Kiniksa is to also receive an additional $20m to be paid when Genetech receive specific drug supplies, as well as an expected $600m from future milestones.
The antibody asset, brought by Kiniksa from Biogen for $11.5m in 2016, is currently undergoing a Phase IIb trial for patients with the inflammatory skin disease prurigo nodularis, having recently met the primary endpoint in a Phase IIa trial and landed a breakthrough lag.
Upon finalization of the current clinical trial, Genetech will handle all future development and commercialization costs of vixarelimab.